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symptoms, and CO levels in exhaled air were determined 
during the three phases. The participants in the control 
group underwent the same MR protocol. In the smokers, 
during withdrawal, the insular cortex showed a significant 
increase in glutamine (Gln; p = 0.023) as well as a slight in-
crease not reaching significance for glutamine/glutamate 
(Glx; p = 0.085) and a nonsignificant drop in myoinositol (mI; 
p = 0.381). These values tended to normalize after oral nico-
tine substitution treatment, even though differences were 
not significant: Gln (p = 0.225), Glx (p = 0.107) and mI (p = 
0.810). Overall, the nonsmokers (control group) did not show 
any metabolic changes over all three phases (p  1 0.05). In 
smokers, acute nicotine withdrawal produces a neurometa-
bolic reaction pattern that is partly reversed by the adminis-
tration of an oral nicotine substitute. The results are consis-
tent with the expression of an addiction-specific neuromet-
abolic shift in the brain and confirm the fact that the insular 
cortex seems to play a possible role in nicotine dependence. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 The aim of this study was to clarify whether addiction-spe-
cific neurometabolic reaction patterns occur in the insular 
cortex during acute nicotine withdrawal in tobacco smokers 
in comparison to nonsmokers. Fourteen male smokers and 
10 male nonsmokers were included. Neurometabolites of 
the right and the left insular cortices were quantified by 
magnetic resonance spectroscopy (MRS) on a 3-Tesla scan-
ner. Three separate MRS measurements were performed in 
each subject: among the smokers, the first measurement 
was done during normal smoking behavior, the second mea-
surement during acute withdrawal (after 24 h of smoking ab-
stinence), and the third shortly after administration of an oral 
nicotine substitute. Simultaneously, craving, withdrawal 
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 Introduction 
 Nicotine abuse is the leading cause of avoidable death 
and the most important cause of morbidity worldwide 
 [1–3] . Although many patients who are addicted to nico-
tine would like to cease smoking, less than 50% are actu-
ally able to achieve sustained abstinence from smoking 
 [4, 5] . The reasons for nicotine dependence are manifold 
and are only partially understood. In addition to known 
social, environmental, and psychological prerequisites, 
a genetic predisposition appears to be associated with a 
greater risk of nicotine dependence  [6–9] . Investigations 
conducted in persons addicted to nicotine showed that 
chronic nicotine abuse may cause significant morpho-
logical changes in various structures of the brain, in-
cluding the insular cortex  [10, 11] . In contrast to other 
imaging modalities such as positron emission tomogra-
phy, functional magnetic resonance imaging (MRI), or 
conventional MRI of the brain,  1 H-MR spectroscopy 
(MRS) enables the investigator to measure biochemical 
changes in a specific region of the brain. Especially neu-
rometabolic reactions in the insular cortex are of great 
interest because the insula contributes significantly to 
central processing of cognitive, social, and emotional 
stimuli  [12] . A noteworthy, recently published study in 
 Science proved that nicotine addiction disappeared 
spontaneously in patients suffering from trauma with 
associated morphological damage within the insular 
cortex  [13] . 
 Consequently, based on this previous publication, the 
aim of the present prospective study was to investigate the 
neurometabolic role of the insular cortex with the aid of 
 1 H-MRS in subjects suffering from tobacco dependence. 
We intended to determine MRS changes during acute 
withdrawal and after oral treatment with a nicotine sub-
stitute compared to a nondependent control group. We 
hypothesized that the results will give a more detailed 
insight of the neurometabolic reaction of the brain, and 
more specifically of the insular cortex, to acute nicotine 
addiction and withdrawal.
 Materials and Methods 
 Data Collection 
 This prospective clinical study, which was approved by the lo-
cal institutional review board, was conducted from January 2011 
to January 2012. All participants were given detailed information 
about the experimental procedure, and thereafter they provided 
written informed consent. To exclude possible hormonal effects 
during the menstrual cycle in women, only men were recruited. 
Further, participants taking medications such as opioids, seda-
tives or other psychopharmacological drugs were excluded. Thus, 
male persons  1 18 years of age, with no general contraindication 
to MRI investigation, were included in the study. 
 Study Population 
 Smokers 
 One hundred and fifty-one smokers were approached during 
their hospital stay. Of these, 135 heavy smokers refused to par-
ticipate in the study. Two participants were subsequently excluded 
from the study because of noncompliance. Overall, 14 male smok-
ers aged 50.43  8 12.57 years (mean  8 SD) were finally recruited 
for the investigation.
 Smokers reported a mean duration ( 8 SD) of smoking of 33.64 
 8 13.93 years; they smoked at least 28.57  8 10.27 cigarettes/day. 
Smokers reported a mean of 1.21  8 1.48 previous attempts to quit 
smoking. None of the smokers had an underlying psychiatric dis-
ease or any other addiction, which was confirmed by a compre-
hensive psychiatric investigation. None of the participants con-
sumed medications like opioids, sedatives, or similar drugs that 
potentially influence neurometabolic reactions. All subjects were 
given the option to participate in a smoking cessation program 
free of charge subsequent to the experiment. Sociodemographic 
and clinical characteristics of the study population are presented 
in  tables 1 and  2 . 
 Control Group 
 Staff members of our hospital, with no previous psychiatric 
disease, no nicotine addiction (nonsmokers along their whole life) 
and absence of addictive diseases, which was confirmed by a pre-
ceding psychiatric investigation, were recruited as controls. The 
participants also had no general contraindication to MRI. Thus, 
10 male nonsmokers with a mean age of 36.6  8 9.24 years were 
included in the study.
 Psychometric Measures 
 Three separate MR experiments were performed, as described 
in detail later on. During the baseline session (1st MRI), partici-
pants completed self-report measures to assess the history and 
level of their nicotine dependence. The absence of psychiatric ax-
is-I comorbidity was verified with the Structured Clinical Inter-
view, which is based on DSM-IV criteria (American Psychiatric 
Association, 2000)  [14–16] . The Fagerström Questionnaire for 
Nicotine Dependence was used to assess the level of nicotine de-
pendence  [15, 16] .
 Nicotine craving (2nd and 3rd MRI) was determined using a 
self-report with the Questionnaire of Smoking Urges (QSU) at 
baseline, after withdrawal and after nicotine treatment (German 
version)  [17–19] . Participants provided a self-report of nicotine 
withdrawal symptoms using the Minnesota Nicotine Withdrawal 
Scale (MNWS) at baseline, withdrawal phase and after nicotine 
treatment  [19] . 
 First Measurement (Baseline) 
 Smokers and nonsmokers were examined using MRI. Addi-
tionally, all participants in the smoker group were asked to com-
plete a Fagerström Questionnaire for Nicotine Dependence, 
MNWS and QSU. An attending psychiatrist explained how the 
questionnaires had to be filled in. 
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  Members of the smokers’ group were asked to continue their 
usual smoking behavior on the 1st day of the experiment. To ver-
ify smoking behavior, participants underwent expired carbon 
monoxide measurements at baseline. The CO breath test was 
measured before MRS (see technical details below). 
 The control group (nonsmokers) pursued their usual daytime 
obligations and a CO breath test was also performed.
 Second Measurement (‘Stimulation Phase’ after Withdrawal) 
 Smokers and nonsmokers were reexamined with MR within 5 
days according to possible free slots in our scanner management. 
Smokers had to completely abstain from smoking for 24 h prior 
to the second measurement. Before starting the MR investigation, 
the MNWS and QSU were again filled in by all study participants 
in order to document their current state of well-being and level of 
craving. CO values in expired air were measured again in order to 
document the withdrawal status and confirm compliance. Par-
ticipants with CO values  1 5 mg/dl were excluded from the study 
as we assumed that they were noncompliant and had smoked in 
between, thus violating the previous agreement. 
 Nonsmokers did not change any habits and underwent the 
identical psychometric tests as well as the second MR examina-
tion.
 Third Measurement (after Stimulation: Substitution/
Treatment with Nicotine Tablets) 
 After completion of the second MR measurement, we removed 
the study participants from the MR device for 40 min. Immedi-
ately after MRI, members of the smoking group received a sublin-
gual nicotine tablet (Nicorette  , 2 mg; Janssen-Cilag AG, Baar, 
Switzerland), which they placed under the tongue in order to dis-
solve for 20 min. The nonsmokers could relax and were permitted 
to drink a glass of water between the two MR examinations. No 
nicotine tablet was given to the nonsmokers.
 Members of both groups were then asked to fill in the ques-
tionnaires once again in order to record the changes in their crav-
ing and basic psychological status.
 Thereafter, smokers and controls were investigated a third 
time by MRS. The entire experiment is summarized in a sche-
matic diagram ( fig. 1 ).
 Experimental Investigations by  1 H MRS 
 The subjects were positioned supine in a 3-Tesla MR unit 
(Achieva, release 2.6.1; Philips Healthcare, Best, The Nether-
lands). A common 4-channel T/R head coil (Philips Healthcare) 
was used. To prevent involuntary head movements, small foam 
cushions were placed between the head coil and the volunteer’s 
Table 1.  Demographic data of the smokers and nonsmoking controls 
Parameters Smokers 
(n = 14)
Nonsmokers 
(n = 10)
Age, years 50.43812.57 36.689.24
Cigarettes smoked on baseline day, n 22.2188.64 080
Exhaled CO at baseline, ppm 23.21810.14 2.7582.63
FTND 7.0781.64 0.0
Cigarettes/day, n 28.57810.27 0
Age at smoking onset, years 16.7982.89 –
Years smoked, n 33.64813.93 0
I nitial measurements in the smokers performed during normal smoking behavior yielded high CO values 
in exhaled air. FTND = Fagerström Test for Nicotine Dependence. The healthy control group, with no exposure 
to smoking, had normal respiratory gas values at the first as well as the second measurement. Means 8 SD.
Table 2.  Smokers: psychological and clinical information
Parameters Baseline Withdrawal 
phase
Nicotine 
substitute phase
Exhaled CO, ppm 23.21810.14 3.5781.95 –
MNWS 0.2980.61 10.7184.50 1.1481.17
QSU 104.21821.79 155.64831.10 110.86833.43
S mokers presented normal psychological values (craving) at baseline (during the initial phase with normal 
smoking behavior). Their urge to smoke (QSU) and nicotine withdrawal symptoms (MNWS) increased sig-
nificantly after 24 h of withdrawal (p < 0.001), and was obviously reduced directly after oral administration of 
a nicotine substitute (phase 3). CO values fell significantly after 24-hour withdrawal of tobacco (p < 0.001). 
Means 8 SD.
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head. The standardized MR protocol consisted of a scout, a refer-
ence scan, and a transverse, sagittal and coronary T1-weighted 
morphological sequence, followed by  1 H spectroscopic measure-
ments ( table 3 ). 
 The left and the right insular regions were measured using the 
 1 H spectroscopy PRESS sequence (point-resolved spectroscopy). 
Volumes of interest (determined for each subject) were placed over 
the entire insula by an experienced board-certified radiologist 
with 13 years of neuroradiological experience including MRS in-
vestigations of the insular cortex (investigator A. Gutzeit/blinded 
for review). 
 Postprocessing and Evaluation of MRS Data 
 For quantification, spectroscopic data were exported and ana-
lyzed with an LCModel using a basic spectrum for echo time (30 
ms) and field strength (3 T) for relevant metabolites. The neuro-
metabolites included choline, creatine, N-acetyl aspartate, gluta-
mate (Glu), glutamine (Gln), Gln/Glu (Glx), myoinositol (mI), al-
anine, lactate, aspartate, and others. The technique we used has 
been described previously  [20] . Fit was achieved within a chemi-
cal shift range between 0.5 and 4.2 ppm. All postprocessing re-
sults are calculated with the measured signal of unsuppressed wa-
ter, which leads to absolute concentration (in mmol/l). 
 Statistical Analysis 
 Descriptive statistics are given as means  8 SD. Data were ana-
lyzed using SPSS (version 20; IBM Corp., Armonk, N.Y., USA). The 
study design could not be equalized for smokers and nonsmokers 
because nonsmokers were naturally not able to undergo a pharma-
ceutical intervention which was comparable to that of the smokers. 
Thus, those two groups were analyzed separately with a repeated-
measure general linear model (GLM) to analyze changes between 
the three measurements. The Mauchly test of sphericity was used 
to control for variance homogeneity and the Greenhouse-Geisser 
correction was applied where appropriate. Pairwise comparisons 
(phases 1 vs. 2; and 2 vs. 3) were also performed. Hence, the sig-
nificance level was set at   = 0.025 to correct for multiple com-
parisons (Bonferroni correction). To further reduce the number of 
comparisons, repeated-measure GLM and pairwise comparisons 
were run with the mean metabolite values between left and right 
sides. Overall, there were no significant differences between the 
right and left brain hemisphere. All other intragroup comparisons 
(CO) were analyzed with a paired-sample t test.
a b c
 Fig. 1. Experimental setup for the smoker 
group. In phase 1, smokers demonstrate 
‘normal’ smoking behavior ( a ). After 24 h 
of tobacco withdrawal, the insular cortex 
was reinvestigated by MRS during pro-
nounced acute withdrawal symptoms 
(phase 2;  b ). To relieve withdrawal symp-
toms, smokers were given an oral nicotine 
substitute 40 min before the subsequent 
third MRS measurement (phase 3;  c ). 
CHO = Choline; Crea = creatine; NAA = 
N-acetyl aspartate. 
Table 3. M R pulse sequence parameters
Parameters T1 1H-MRS PRESS
TR, ms 600 2,000 
TE, ms 10 30 
Slice thickness, mm 4 –
Voxel size, mm 0.9 ! 1.12 VOI: 20 ! 20 ! 37.5
NSA 1 96
Acquisition time, min 2.07 3.48 
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 Results 
 All single-voxel MRS measurements fulfilled the qual-
ity requirements and thus could be evaluated both in the 
smokers as well as the nonsmokers using the LCModel 
evaluation method.
 The repeated-measure GLM found a significant with-
in-subject effect for both QSU (F 2 = 21.670, p  ! 0.001) and 
MNWS (F 2 = 71.686, p  ! 0.001; Greenhouse-Geisser cor-
rection: F 1.129 = 71.686, p  ! 0.001). Exhaled air CO levels 
decreased significantly between baseline and withdrawal 
phase (smoker group) 24 h later (baseline 23.21  8 10.14; 
withdrawal phase 3.57  8 1.95; p  ! 0.001). Concomitant-
ly, the urge to smoke (QSU: baseline 104.21  8 21.79, with-
drawal phase 155.64  8 31.10; p  ! 0.001), and nicotine 
withdrawal symptoms (MNWS: baseline 0.29  8 0.61, 
withdrawal phase 10.71  8 4.50; p  ! 0.001) increased sig-
nificantly in the smoker group versus baseline in the 
withdrawal phase. After oral treatment with 2 mg of nic-
otine, the withdrawal symptoms and craving were sig-
nificantly improved (p  ! 0.001) and returned almost to 
baseline levels ( table 2 ). Members of the nonsmoker group 
had no relevant test changes or signs of addiction during 
the three measurements. 
 Metabolic Changes 
 The metabolite patterns of Glx, Gln, Glu and mI dem-
onstrated a stimulation effect in both insular regions and 
are shown in  table 4 a–d. Insular levels of these metabo-
lites changed during nicotine withdrawal compared with 
 
a Glutamine
Phase Mean 95% CI
Smokers
1 3.582 3.189–3.974
2 4.086 3.555–4.617
3 3.727 3.196–4.258
Nonsmokers
1 2.519 1.740–3.298
2 2.658 2.090–3.226
3 2.780 2.150–3.410
There was no significant within-subject effect for the smokers 
(F2 = 1.867, p = 0.175). Gln demonstrated a significant increase 
between baseline and withdrawal phase (p = 0.023). After admin-
istration of the nicotine substitute, Gln levels reversed, showing a 
minimal, nonsignificant drop (p = 0.225).
b Glutamine/glutamate 
Phase Mean 95% CI
Smokers
1 10.424 9.735–11.114
2 11.106 10.333–11.879
3 10.463 9.663–11.264
Nonsmokers
1 9.070 8.069–10.070
2 9.089 8.058–10.120
3 9.253 8.346–10.160
There was no significant within-subject effect for the smokers 
(F2 = 1.676, p = 0.207). A minimal increase between phases 1 and 
2 (p = 0.085) was noted, as well as a minimal drop between phas-
es 2 and 3 (p = 0.107).
c Glutamate
Phase Mean 95% CI
Smokers
1 6.843 6.481–7.204
2 7.020 6.698–7.343
3 6.736 6.382–7.090
Nonsmokers
1 6.551 6.061–7.041
2 6.430 5.866–6.995
3 6.473 6.082–6.864
For the smokers, the within-subject effect gave the following 
results: F2 = 0.289, p = 0.302; pairwise comparisons between phas-
es 1 and 2 (p = 0.375), and phases 2 and 3 (p = 0.040).
d Myoinositol
Phase Mean 95% CI
Smokers
1 5.508 5.033–5.983
2 5.330 5.014–5.645
3 5.371 4.994–5.749
Nonsmokers
1 5.242 4.804–5.681
2 5.291 4.814–5.767
3 5.248 4.705–5.792
For the smokers, the within-subject effect gave the following 
results: F2 = 0.530, p = 0.595; pairwise comparisons between phas-
es 1 and 2 (p = 0.381), and phases 2 and 3 (p = 0.810).
Table 4. Absolute MRS results for Gln, Glx, Glu, and mI: estimated marginal means and 95% confidence intervals (CI) for smokers 
and nonsmokers at time points 1–3
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healthy controls and as well when comparing within sub-
jects. These metabolites partly returned to baseline after 
oral application of a nicotine substitute. All other docu-
mented brain metabolites, such as choline, N-acetyl as-
partate, Glu, alanine, lactate and aspartate, showed no 
tendency and no significant changes and are not dis-
cussed further. 
 Metabolic Changes in the Smokers  
 Glutamine  
 Although the within-subject effect is not significant 
(F 2 = 1.867, p = 0.175), Gln demonstrated a significant in-
crease between phases 1 (baseline) and 2 (withdrawal 
phase; p = 0.023) at group level. After administration of 
the nicotine substitute, levels of the metabolite reversed, 
showing a minimal, nonsignificant drop between phases 
2 (withdrawal phase) and 3 (withdrawal with nicotine 
tablet; p = 0.225;  table 4 a). 
 Glutamine/Glutamate 
 Both the within-subject effect (F 2 = 1.676, p = 0.207) 
and the pairwise comparisons at group level were not sig-
nificant. We observed a discrete increase between phases 
1 and 2 (p = 0.085), and a nonsignificant drop between 
phases 2 and 3 (p = 0.107;  table 4 b). 
 Glutamate 
 The within-subject effect was not significant (F 2 = 
0.289, p = 0.302), and pairwise comparisons at group lev-
el between phases 1 and 2 did not significantly differ
(p = 0.375). A nonsignificant drop in Glu occurred be-
tween phases 2 and 3 (p = 0.040;  table 4 c).
 Myoinositol  
 The within-subject effect was not significant (F 2 = 
0.530, p = 0.595); there was only a slight drop during the 
withdrawal phase (p = 0.381) and a return to the baseline 
level after application of nicotine without achieving sta-
tistical significance (p = 0.810;  table 4 d). 
 Metabolic Changes in the Control Group 
 As expected, no significant changes in the above-men-
tioned three metabolites were observed in the control 
group between the three time points corresponding to 
the single MR experiments ( table 4 ).
 The attempt to correlate MRS data with any of the psy-
chological tests was not feasible from the methodological 
point of view. The internationally standardized question-
naires have a completely different focus excluding direct 
comparison with MRS data.
 Discussion 
 As nicotine dependence is widespread and has signif-
icant health-related sequelae for smokers, it constitutes a 
major problem for society as a whole. Although this type 
of addiction is widespread, it was recognized as an addic-
tive disease only in the late 1980s  [5, 21] . The reasons for 
tobacco dependence are manifold. In addition, social, 
psychological, environmental, and genetic factors play an 
important role  [6, 7] . Achieving smoking cessation on a 
permanent basis can be extremely difficult  [22, 23] . Better 
understanding of the pathophysiology of addiction and 
associated metabolic processes within the brain is thus of 
outmost importance.
 Due to its numerous functions, the insular cortex ap-
pears to play a special role in the development of addic-
tion  [10, 11, 13] . Indeed, following traumatic injury of the 
insula, smokers were spontaneously able to cease smok-
ing without any craving  [13] . 
 In accordance with these earlier findings, MRS is a 
promising diagnostic tool to analyze the neurometabolic 
activity of the insular cortex. Using MRS, the brain’s en-
dogenous substances and metabolites can be measured in 
a noninvasive manner, and conclusions can be drawn 
about physiological intracellular changes  [24] .
 Recent studies have shown that specific stimuli such 
as pain or anxiety may markedly influence spectroscopic 
conditions in the brain metabolically  [25, 26] . Further-
more, MRS is successfully used in various addictive dis-
orders to elucidate their pathophysiology and withdrawal 
 [27–29] . 
 The present investigation showed that nicotine depen-
dence causes shifts in levels of specific metabolites in the 
insular region during acute nicotine withdrawal ( fig. 2 ). 
The changes specifically concern three metabolites: Gln, 
mI, and Glx. Changes in mI (drop between baseline and 
withdrawal phase) and Glx (increase between baseline and 
withdrawal phase) only show a tendency to a statistical dif-
ference. However, a significant increase in Gln was noted 
during acute nicotine withdrawal. This specific difference 
cannot be explained by previously published or our own 
results. The encountered changes were reversible after oral 
administration of a nicotine substitute. In contrast to the 
smoker group, the (nonsmoking) control group revealed 
an absolute stable metabolic level over all three phases 
demonstrating good reproducibility of our measurement 
technique and a well-designed study protocol.
 Nevertheless, our data should be interpreted with 
great caution. They show that smoking withdrawal causes 
metabolic changes in the insula, which are partly re-
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versed by oral administration of a nicotine substitute. In-
deed, due to the relatively low number of subjects includ-
ed and the relatively low or nonexistent significance, it is 
still too early to define this pattern as an addiction-spe-
cific reaction of the brain. It is remarkable that the most 
abnormal neurometabolic values (compared to controls) 
are those obtained during withdrawal. One possible ex-
planation is that the smoking state is the ‘normal’ state for 
those who are dependent. This could be a possible reason 
for the metabolic changes during withdrawal. 
 Moreover, the results appear comparable to other MRS 
investigations under different stress conditions. Hence, 
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 Fig. 2. Overview of MRS data: metabolites 
Gln, Glx, Glu, and mI for smokers (n = 14) 
during smoking, withdrawal (Detox), and 
after sublingual administration of a 2-mg 
nicotine tablet (left column) and for the 
control group (non-smokers; n = 10) dur-
ing the first, second and third measure-
ments (right column) are displayed. Due to 
the lack of a significant difference between 
the right and left hemispheres, neurome-
tabolites are reported together. 
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these recently published studies showed that acute artifi-
cially produced dental pain causes metabolic shifts in the 
insula that were, in part, very similar to those observed 
in the present study  [30, 31] . The aforementioned investi-
gation showed increases in Gln and Glx as well as a drop 
in ml during the acute phase of pain, all of which resolved 
immediately after cessation of the external stimulus. Al-
though the study designs with pain and here nicotine ad-
diction differ strongly thus questioning comparison, the 
results do reveal marked similarities regarding metabolic 
dynamics in the ‘stimulation phase’ (nicotine withdrawal 
vs. pain stimulus) and the subsequent ‘recovery phase’ 
(decreasing withdrawal effects by the administration of 
oral nicotine vs. stopping the pain stimulus). It seems, 
even though not conclusive, that the brain reacts quite 
similarly in such stress situations at a neurometabolic lev-
el, especially for Gln and Glx. According to the physio-
logical theory, Glu released from neurons is predomi-
nantly removed by astrocytic cells, which react by pro-
ducing a constant Gln flow from astrocytes to neurons 
 [32] . The question arises why much greater metabolic 
changes are observed in the insular region during acute 
pain compared to nicotine withdrawal, as recorded in our 
study: we presume that acute pain triggers a much stron-
ger stress signal than nicotine withdrawal from a physi-
ological point of view. This would explain the much more 
intense neurometabolic pattern within the brain. More-
over, regarding comparison, artificially induced pain can 
be much better standardized than a highly variable and 
rather subjective stimulus resulting from nicotine with-
drawal. Pain impulses can be induced and stopped from 
one moment to the next, whereas nicotine withdrawal 
symptoms usually start slowly, and their severity and de-
velopment are variable in individuals and over longer 
time periods. Furthermore, nicotine withdrawal does not 
merely entail a somatic component, but also involves psy-
chological factors, which can be analyzed on the basis of 
questionnaires in an experiment of this nature, but can-
not really be eliminated. All these different influencing 
factors must be taken into account when analyzing more 
profoundly neurometabolic behavior in patients suffer-
ing from addictive diseases. 
 Indeed, we cannot postulate a tobacco-specific reac-
tion pattern due to the preliminary nature of our study. 
Nevertheless, we assume that nicotine withdrawal results 
in general neurometabolic stimulation. Overall this is 
speculative and cannot be proven. However, further stud-
ies will be needed to determine how metabolites in the 
insula react to other stressors such as hunger, cold, or 
other stressful stimuli, e.g. addiction.
 We cannot explain the reason for the drop in mI and 
the rise in Gln and Glx observed in this study. Neverthe-
less, previous studies addressing addictive diseases and 
conditions such as alcohol withdrawal demonstrated 
comparable changes in specific metabolite levels with 
MRS  [33] . Thus, neurometabolic changes might not only 
occur in the presence of nicotine withdrawal but possibly 
also in other types of withdrawal symptoms.
 The metabolites Gln and Glu are important neuro-
metabolic excitatory amino acids in the brain and thus 
one of the most important transmitter substances of the 
brain for any type of signal transmission. Gln results 
from the metabolic transformation of Glu, which is pro-
duced in astroglial cells of brain synapses. It is assumed 
that a large part of the brain’s energy consumption is 
caused by the production of these metabolites alone  [34–
37] . This confirms once again our assumption: increases 
in these metabolite levels are possibly not a smoker-spe-
cific change, but a general sign of a ‘stress-related neu-
rotransmitter reaction’, which is also observed in with-
drawal. It must be emphasized that MRS quantification 
especially of Gln is still limited due to high standard de-
viations and technical limitations. Therefore, further in-
terpretation of Gln must be done with appropriate cau-
tion. Nevertheless, the observed Gln shifts were only 
marked in the smokers whereas the nonsmokers did not 
show any difference among the three measurements. 
 For the time being, the minimal reduction in mI is dif-
ficult to explain from a biological point of view. To the 
best of our knowledge, no comparable descriptions in re-
lation to addiction have been published. However, a sim-
ilar drop in mI has also been noted in the acute phase of 
pain stimulation  [25, 30, 31] .
 In addition to shifts in metabolite levels among smok-
ers, as shown in the present study, the impact of tobacco 
on the structure of the brain is a well-known phenome-
non. Several studies have shown that nicotine exerts a 
direct toxic effect on the brain reducing its volume  [10, 
38, 39] . How far the metabolic shifts observed in the pres-
ent study are a consequence of this toxic impact cannot 
be stated with certainty. It would also be very interesting 
to determine how the spectra change in smokers while 
they undergo various withdrawal treatments consisting 
of psychotherapy, e.g. behavioral therapy. From a func-
tional neurological perspective, the insular cortex is a 
very complicated structure, which is divided into ante-
rior and posterior insular subdivisions. The posterior 
part is generally associated with sensorimotor function, 
including perception of pain, cold, heat, and other stim-
uli  [12, 40–42] . In contrast, the anterior insula is not tra-
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ditionally associated with somatosensory-related pro-
cessing and seems to be rather involved in empathy and 
emotions  [12, 43–45] . 
 According to these functional subdivisions, the insu-
lar cortex in general might play an important role in nic-
otine addiction. Further studies investigating the effect of 
nicotine on this complicated part of the brain are re-
quired. Thus, it would be necessary to evaluate the meta-
bolic reaction differentiating the discrete reactions of the 
anterior and posterior parts of the insular cortex under 
acute addiction. 
 There are several limitations of the present study. The 
group of smokers was rather small, possibly explaining 
the low significance recorded in the present study. Nev-
ertheless, it should be emphasized that due to the pilot 
study methodology we did not have any databases for 
power analysis prior to the beginning of the investigation. 
One further limitation relates to the fact that we only 
measured metabolic reactions in the insular cortex. We 
thus cannot exclude the possibility that the metabolic 
changes might also occur in other brain areas. Moreover, 
MRS measurements are relatively time consuming; thus 
it is not possible to measure more than one brain region 
within an acceptable time. Furthermore, the control 
group consisting of healthy nonsmokers could not be giv-
en an oral nicotine substitute during the third phase be-
cause the local ethics committee objected to such an in-
tervention. Therefore, the study conditions were not en-
tirely identical for both groups, at least not during phase 
3. Another possible limitation might be that we cannot 
exclude various external influences such as daytime or 
nutritional effects, for example. In addition, only male 
smokers and nonsmokers were included to prevent any 
hormonal influence, which might be another limiting 
factor. Finally, the control group and the smoker group 
were not matched for age. Thus, possible age-related 
structural brain differences could not be excluded as a 
possible source of metabolic differences.
 Conclusions 
 Nicotine withdrawal is associated with significant in-
creases in Gln levels in the insular cortex, which resolve 
after oral administration of a nicotine substitute. In the 
case of Glx and mI, changes are relatively discrete and 
nonsignificant under acute withdrawal, tending to reach 
baseline levels after oral administration of a nicotine sub-
stitute. Thus, it may be assumed that nicotine depen-
dence is associated with specific reaction patterns, sug-
gesting a pivotal role of the insular cortex.
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